Translational Data at SITC 2021 from Adaptimmune’s Phase 1 SURPASS Trial Indicate Adding AKTi to Manufacturing May Contribute to Sustained Antitumor Activity of Next-gen SPEAR T-cells November 12, 2021 GlobeNewswire Source: Manufacturing Share on Facebook Share Share on TwitterTweet Share on Google Plus Share Share on Pinterest Share Share on LinkedIn Share Share on Digg Share